Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics
Source: Streetwise Reports (04/13/2026)
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.
read more >
MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA
Source: Robert Burns (04/13/2026)
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
read more >
Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion
Source: Streetwise Reports (04/08/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.
read more >
California Biotech Co. Advances Depression Drug Breakthrough
Source: Streetwise Reports (04/07/2026)
Alto Neuroscience Inc. (ANRO:NYSE) pivots after mixed trial results, targeting treatment-resistant depression with analyst support and major market growth potential.
read more >
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial
Source: Dr. Ananda Ghosh (04/07/2026)
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
read more >